Scarica l'app Stockscreener
96.46
2.28%
2.15
Precedente Chiudi:
$94.31
Aprire:
$94.19
Volume 24 ore:
538.69K
Relative Volume:
0.76
Capitalizzazione di mercato:
$6.41B
Reddito:
$136.86M
Utile/perdita netta:
$-168.69M
Rapporto P/E:
-34.33
EPS:
-2.81
Flusso di cassa netto:
$-113.49M
1 W Prestazione:
+8.91%
1M Prestazione:
+11.26%
6M Prestazione:
+67.35%
1 anno Prestazione:
+116.86%
Intervallo 1D:
$93.55
$96.65
Intervallo di 1 settimana:
$87.99
$96.65
Portata 52W:
$43.57
$96.65
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
Nome
Rhythm Pharmaceuticals Inc
Settore
Industria
Telefono
857-264-4280
Indirizzo
222 BERKELEY STREET, BOSTON, MA
Confronta RYTM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
96.46 | 6.26B | 136.86M | -168.69M | -113.49M | -2.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-10 | Iniziato | Goldman | Buy |
| 2025-07-07 | Iniziato | Leerink Partners | Outperform |
| 2025-04-07 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-03-05 | Ripresa | Stifel | Buy |
| 2025-01-02 | Iniziato | Jefferies | Buy |
| 2024-12-20 | Iniziato | Oppenheimer | Outperform |
| 2024-10-21 | Iniziato | Guggenheim | Buy |
| 2024-09-18 | Iniziato | H.C. Wainwright | Buy |
| 2024-09-17 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-05-08 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-12-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-08-01 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-01-18 | Ripresa | Canaccord Genuity | Buy |
| 2022-08-08 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-08-05 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-06-17 | Reiterato | Needham | Buy |
| 2022-03-02 | Ripresa | Stifel | Buy |
| 2022-02-17 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2021-12-08 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-14 | Ripresa | Goldman | Neutral |
| 2021-08-04 | Downgrade | BofA Securities | Neutral → Underperform |
| 2021-08-04 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-30 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-01-08 | Iniziato | Goldman | Sell |
| 2019-07-12 | Aggiornamento | Stifel | Hold → Buy |
| 2019-07-08 | Iniziato | Canaccord Genuity | Buy |
| 2019-03-13 | Iniziato | Ladenburg Thalmann | Buy |
| 2018-09-07 | Ripresa | Morgan Stanley | Overweight |
| 2018-06-25 | Reiterato | Needham | Buy |
| 2018-06-15 | Reiterato | Needham | Buy |
| 2017-10-30 | Iniziato | BofA/Merrill | Buy |
| 2017-10-30 | Iniziato | Needham | Buy |
Mostra tutto
Rhythm Pharmaceuticals Inc Borsa (RYTM) Ultime notizie
Rhythm Pharmaceuticals stock hits all-time high at 95.05 USD By Investing.com - Investing.com Nigeria
Can Rhythm Pharmaceuticals’ (RYTM) Revenue Growth Offset Persistent Losses in Its Path to Profitability? - simplywall.st
Rhythm Pharmaceuticals prices $175M stock offering - MSN
Rhythm Pharmaceuticals Inc. Forms Bullish Flag — Upside AheadSmart Allocation Stock Pick Insights Gaining Interest - beatles.ru
Rhythm Pharmaceuticals: Unlocking Value as Key Lock-Up Expiry and Setmelanotide Regulatory Milestones Loom - AInvest
Rhythm Pharmaceuticals and the Impending Lock-Up Expiry: A Catalyst for Shareholder Value Realization - AInvest
Rhythm Pharmaceuticals: A Post-Lock-Up Opportunity with Strong Catalysts in Q3 2025 and Beyond - AInvest
Rhythm Pharmaceuticals Lock-Up Agreement Ends on August 9, 2025 - AInvest
Pediatric Obesity Market Expected to Experience Major Growth by 2034, According to DelveInsight | VIVUS LLC, Novartis, Rhythm Pharmaceuticals, Jack Yanovski - The Globe and Mail
12 Analysts Weigh In on Rhythm Pharmaceuticals: A Comprehensive Analysis of Ratings and Price Targets - AInvest
Rhythm Pharmaceuticals Exceeds Q2 Expectations, Maintains Buy Rating - AInvest
Leerink Partners Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Announces Target Price $102 - 富途牛牛
Strong Q2 Performance and Strategic Investments Drive Buy Rating for Rhythm Pharmaceuticals - TipRanks
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q2 2025 Earnings Call Transcript - Insider Monkey
Rhythm Pharmaceuticals stock price target raised to $100 from $80 at H.C. Wainwright - Investing.com Canada
HC Wainwright Raises PT to $100, Maintains Buy Rating on Rhythm Pharmaceuticals. - AInvest
Loss-Making Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Expected To Breakeven In The Medium-Term - Yahoo Finance
Rhythm Pharmaceuticals’ Earnings Call Highlights Growth and Challenges - TipRanks
Positive Outlook on Rhythm Pharmaceuticals: Strong Growth Potential and Strategic Advancements Support Buy Rating - TipRanks
Guggenheim Raises Rhythm Pharmaceuticals Buy Rating, PT to $120 - AInvest
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates - MSN
Citizens JMP raises Rhythm Pharmaceuticals stock price target to $135 on growth - Investing.com Canada
Rhythm Pharmaceuticals shares rise 3.30% premarket after reporting Q2 2025 earnings. - AInvest
Rhythm Pharmaceuticals Inc (RYTM) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Rhythm Pharmaceuticals Inc (RYTM) Q2 2025 Earnings Call Highligh - GuruFocus
Rhythm Pharmaceuticals Reports Strong Q2 2025 Growth - TipRanks
Rhythm Pharmaceuticals Q2 Revenue Surpasses Estimates, Up 67% YoY - AInvest
Rhythm Pharmaceuticals: Unlocking Value in Rare Disease Innovation and Commercial Scalability - AInvest
Rhythm Pharmaceuticals Achieves 29% QoQ Revenue Growth, Sets Sights on HO Regulatory Filings - AInvest
Rhythm Pharmaceuticals' Q2 2025: Navigating Key Contradictions in Trial Design, Stock Compensation, and Market Dynamics - AInvest
Needham Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $95 - 富途牛牛
Rhythm Pharmaceuticals stock price target raised to $110 from $85 at TD Cowen - Investing.com Canada
Rhythm Pharmaceuticals price target raised to $109 from $100 at Morgan Stanley - TipRanks
Rhythm Pharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat
Positive Outlook for Rhythm Pharmaceuticals: Strong Revenue Performance and Promising Future Catalysts Justify Buy Rating - TipRanks
Rhythm Pharmaceuticals Q2 2025 slides: Revenue jumps 29%, obesity drugs show promise - Investing.com Canada
Rhythm Pharmaceuticals Fiscal Q2 Net Loss Widens, Revenue Rises - MarketScreener
Rhythm Pharmaceuticals Q2 revenue up 67% yr/yr, net loss widens - MarketScreener
Rhythm Pharmaceuticals Reports Q2 GAAP EPS of -$0.75, Revenue at $48.5 Million - AInvest
Rhythm Pharmaceuticals enrolls first patient in Part C of Phase 1 RM-718 trial - TipRanks
Earnings Flash (RYTM) Rhythm Pharmaceuticals, Inc. Reports Q2 Revenue $48.5M, vs. FactSet Est of $43.6M - MarketScreener
Rhythm Pharmaceuticals Q2 2025 Financial Results and Business Update - TradingView
Rhythm Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Update - The Manila Times
Rhythm Pharmaceuticals Q2 net product revenue $48.5mln, raises $189.2mln. - AInvest
Rhythm Pharmaceuticals to Discuss Q2 Financial Results and Corporate Updates on August 5, 2025 - AInvest
How strong is Rhythm Pharmaceuticals Inc. company’s balance sheetDiscover top stock picks for aggressive growth - Jammu Links News
How does Rhythm Pharmaceuticals Inc. generate profit in a changing economyHigh-margin investment plays - Jammu Links News
What are the latest earnings results for Rhythm Pharmaceuticals Inc.Free Investment Timing Strategies - Jammu Links News
Is it the right time to buy Rhythm Pharmaceuticals Inc. stockAchieve breakthrough financial results today - Jammu Links News
Does Rhythm Pharmaceuticals Inc. stock perform well during market downturnsRapid wealth multiplication - Jammu Links News
Is Rhythm Pharmaceuticals Inc. stock overvalued or undervaluedRecord-breaking gains - Jammu Links News
Rhythm Pharmaceuticals Inc Azioni (RYTM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.91%
3.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):